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Alcohol Screening among Opioid Agonist Patients 
in a Primary Care Clinic and an Opioid Treatment Program 
Abstract: 
Problem alcohol use is associated with adverse health and economic outcomes, especially among 
people in opioid agonist treatment. Screening, brief intervention and referral to treatment 
(SBIRT) are effective in reducing alcohol use; however, issues involved in SBIRT 
implementation among opioid agonist patients are unknown.  To assess identification and 
treatment of alcohol use disorders, we reviewed clinical records of opioid agonist patients 
screened for an alcohol use disorder in a primary care clinic (n =208) and in an opioid treatment 
program (n = 204) over a two year period.    In the primary care clinic, 193 (93%) buprenorphine 
patients completed an annual alcohol screening and six (3%) had elevated AUDIT scores.  
Among the patients treated in the opioid treatment program, an alcohol abuse or dependence 
diagnosis was recorded for 54 (27%) methadone patients. Practitioner focus groups were 
completed in the primary care (n = 4 physicians) and the opioid treatment program (n = 11 
counsellors) to assess experience with and attitudes towards screening opioid agonist patients for 
alcohol use disorders. Focus groups suggested organizational, structural, provider, patient and 
community variables hindered or fostered alcohol screening.  Alcohol screening is feasible 
among opioid agonist patients. Effective implementation, however, requires physician training 
and systematic changes in workflow.  
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Alcohol Screening among Opioid Agonist Patients 
in a Primary Care Clinic and an Opioid Treatment Program 
Introduction 
Patients with opioid use disorders have specific health needs and risk behaviors (O'Toole 
et al. 2008; Klimas et al. 2012). Alcohol use is common.  Up to 40% of patients in opioid 
treatment programs screen positive for an alcohol use disorder (Hartzler, Donovan and Huang 
2010; Ryder et al. 2009) and risk alcohol-related comorbidities (Nyamathi et al. 2009; Bird and 
Robertson 2011; Gossop, Marsden and Stewart 2002; Staiger et al. 2013).   Problem alcohol use 
among opioid agonist patients is associated with adverse health outcomes (Nyamathi et al. 2009; 
Staiger et al. 2013): worsened prognosis among those with chronic hepatitis C (HCV) infection, 
increased risk of fatal opioid overdose (Bird and Robertson 2011) and increased psychological/ 
emotional problems (Nyamathi et al. 2009).   
Despite the potential for problem alcohol use to complicate opioid agonist therapy, there 
is little research on strategies to screen and treat alcohol use disorders among opioid dependent 
individuals. Issues involved in implementation of these strategies among opioid agonist patients 
are unknown. Alcohol use disorders are typically assessed as a safety concern rather than a 
health concern. In Ireland, where general practitioners can prescribe methadone for opioid 
dependent patients, interviews with 39 health professionals noted two major barriers to screening 
for alcohol use disorders among methadone patients: 1) insufficient knowledge, training and 
experience working with patients with alcohol use disorders and 2) a lack of specialist support 
(Childers et al. 2012; Field et al. 2013).  
Screening, brief intervention and referral to treatment (SBIRT) strategies help primary 
care settings identify patients at risk for alcohol and drug use disorders, make brief interventions 
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available to reduce unhealthy levels of use and, when necessary, refer patients to specialized 
treatment services (Office of National Drug Control Policy 2013).  The US Preventive Task 
Force recommends routine SBIRT for alcohol use (Whitlock et al. 2004; Moyer 2013).   
The SBIRT Oregon residency training program (www.sbirtoregon.org) taught primary 
care physicians in federally qualified health centers to conduct SBIRT (Muench et al. 2012; 
Muench et al. 2014). One of the participating federally qualified health centers had a large 
caseload of patients prescribed buprenorphine for opioid dependence. The combination of 
routine SBIRT and buprenorphine for opioid dependent patients permitted an assessment of the 
use of SBIRT for alcohol use disorders (AUDs); focus groups explored staff perceptions of 
conducting alcohol SBIRT.  A nearby non-profit opioid treatment program provided a 
comparison clinic to assess differences in screening for alcohol use disorders.  Variation, 
however, in screening processes, staff training and patient preference (buprenorphine or 
methadone (Wu et al. 2011) limit inter-facility comparisons. Nevertheless, the comparison 
provides insight into identification and treatment of alcohol use disorders in both settings and 
how to improve screening processes. 
Methods 
An exploratory study completed chart reviews and assessed screening and interventions 
for alcohol use disorders among opioid dependent patients.  
Participants. Patients were eligible if they received at least 90 days of buprenorphine or 
methadone treatment between April 1, 2011 and April 1, 2013. Practitioner focus groups 




Settings and health record abstraction.  A federally qualified health center in Portland, 
Oregon had a caseload of 208 eligible buprenorphine patients.  The SBIRT Primary Care 
Residency Initiative in Oregon was implemented from December 2009 - September 2013. The 
program implemented systematic methods for screening in seven health centers and trained 
residents to conduct brief interventions. The study clinic was an SBIRT Oregon site with roughly 
200 active opioid agonist treatment patients receiving buprenorphine; all buprenorphine patients 
should have received an alcohol screening.  Clinic policy required universal, annual screening 
with a three-item tool for alcohol, drugs and depression (Canagasaby and Vinson 2005). Positive 
patients were assessed with three instruments: AUDIT (Alcohol Use Disorder Identification 
Test) (Babor and Higgins-Biddle 2001), DAST (Drug Abuse Screening Test) (Skinner 1982) and 
PHQ (Patient Health Questionnaire) (Kroenke, Spitzer and Williams 2001).   Trained research 
staff retrieved electronic health records for eligible patients and abstracted patient characteristics, 
results of the most recent screen, and alcohol-related interventions, if any, using a form adapted 
from prior research (Field et al. 2013; Cullen et al. 2009).   
The opioid treatment program served approximately 720 active patients receiving 
methadone (51% women); 350 met study eligibility criteria. Alcohol use was assessed at 
admission and during annual medical exams with the SSI-AOD (Simple Screening Instrument 
for Alcohol and Other Drugs) (Center for Substance Abuse Treatment 1994) and DSM-IV.  
Breath and urine ETG (Ethyl Glucuronide) tests were administered if alcohol misuse was 
suspected by the intake counselor.  Trained research staff retrieved electronic health records for 
the first 204 eligible patients (so that the number of chart reviews would be similar in the two 
clinics) and abstracted patient characteristics, results of the most recent alcohol assessment, and 
alcohol-related interventions, if any, using the adapted data form.  We hoped to learn, from the 
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analysis, what was similar or different in the identification and treatment of alcohol use disorders 
among opioid agonist patients in a primary care clinic versus an opioid treatment program. 
Qualitative Data Collection and Analysis. A focus group in each study setting probed 
the clinicians’ experience of screening and treating patients for problem alcohol use and attitudes 
toward screening and assessed barriers and facilitators to routine alcohol screening.  Five steps 
guided qualitative analysis of focus group transcripts: 1) data preparation, transcription and 
familiarization, 2) generation of initial codes, 3) theme assessment, 4) theme review and 5) 
theme finalization (Braun and Clarke 2006; Morgan, Krueger and King 1998).  The first author 
generated themes via computer-assisted qualitative data analysis (CAQDAS). General higher-
order themes were identified within the first half of the transcripts and data saturation occurred 
towards the end of the analysis (Guest, Bunce and Johnson 2006). Two external reviewers 
audited the themes and independently compared the list of themes against the focus-group 
transcripts and suggested corrections where they believed that the theme titles or structure did 
not correspond with transcripts.  Disagreements were resolved by discussion. 
Ethical considerations.  The Institutional Review Board (IRB) at Oregon Health and 
Science University reviewed and approved the study protocol. Focus group participants were 
informed of the study purposes, and voluntary and anonymous participation before they signed 
informed consents. The IRB required removal of patient identifiers from abstracted data before 
the data were released for analysis and online training in responsible conduct of research 
(bigBrain.ohsu.edu) for all study staff.  
Results 
Demographics. In the primary care setting, the mean age of patients was 40.5 years 
(standard deviation: 11.3) and included 126 (60%) women and 169 (81%) with public or 
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commercial health insurance.  In the methadone clinic, the mean age of methadone patients was 
39.8 years (SD 13.7) and included 111 (54%) women and 154 (76%) participants with public or 
commercial health insurance.  
The six buprenorphine physician prescribers in the primary care clinic were invited to 
participate in the focus group; four participated. Participants had a mean age of 40.1 years (range 
28-55 years) and two were women. Eleven health professionals (e.g., counselors, social workers 
and intake staff) working in the opioid treatment program were invited to participate in a focus 
group; 10 attended.  The addiction counselors had a mean age of 40 years (range 24-60) and six 
were women.   
Screening and intervention for alcohol use disorders.  The review of medical records 
from the primary care clinic found completed annual alcohol screens for 193 of the 208 eligible 
patients (95%); 28 (15% of those screened) completed the full AUDIT and six of the screened 
patients (3%) had an elevated AUDIT score (≤7). Five of the primary care buprenorphine 
patients received a brief intervention addressing their alcohol use.   
Patients in the methadone clinic received an alcohol and drug assessment at intake; 54 
patients (27%) received a diagnosis of an alcohol use disorder including 36 (18%) who met 
criteria for alcohol dependence and 18 (9%) for alcohol abuse. During the two year study period, 
the clinic administered 513 breath tests – none were recorded as positive in the patient record.  
Treatment plans are reviewed and updated every 90 days and an alcohol problem was recorded 
for 4% of the patients (n = 8). During the study period, five patients were prescribed disulfiram 
for alcohol dependence with observed dosing daily. 
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Qualitative Analysis. Analysis of the focus group transcripts suggested two major 
themes related to the use of screening and brief intervention for alcohol use disorders: (i) SBIRT 
practices and (ii) implementation issues.   
SBIRT practices: Screening.  The practice of alcohol screening differed in the primary 
care and the specialty care clinics. Both clinics assessed alcohol use at admission.  Ongoing 
screening in specialty care was based on suspicion. Breath testing and ETG (Ethyl Glucuronide) 
tests assessed patients who “acted peculiar” out of concern for safety rather than as routine 
screening. Focus group participants recognized limitations of this approach: “It’s [a] lot easier to 
fly under the radar with alcohol than with other drugs.”  One clinician in the opioid treatment 
program explained that formalized alcohol screens were not used in annual assessments – “We 
do annual assessments, is that the same thing? There’s nothing specific about alcohol on it 
though. I think that it would be good [to add an alcohol screen].” The annual screening process 
in primary care, conversely, was systematized into small steps – a three-item screen and full 
AUDIT screen for positives – each performed by different staff. This process ensured that most 
patients were screened.  Physicians reported patient acceptance and support, “Mostly the patients 
were like: I’m really glad you care about me as a whole person.” 
SBIRT Practices: Brief intervention and treatment.  Physicians in the primary care clinic 
delivered a brief psychosocial intervention to patients who screened positive on the AUDIT. 
They acknowledged that some patients did not receive the brief intervention because of practice 
distractions, record deficits and a lack of attention to problem alcohol use in this patient sub-
group, “Alcohol just seems so inane compared to shooting heroin.” Standard pharmacotherapy 
was available for treatment of alcohol use disorders according to the primary care participants.  
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The specialty care clinic, on the other hand, managed alcohol use disorders with disulfiram 
delivered and observed during daily methadone dosing. Inpatient or outpatient detoxification 
while on methadone was offered as needed. The clinic’s residential treatment facility permitted 
patients to remain on methadone. Counselors delivered psychosocial interventions in a one-to-
one or group format; however, none of them were alcohol specific. 
 SBIRT practices: Referral.  Both clinics highlighted the role of referral to treatment of 
alcohol use disorders.  Family physicians depended upon a “warm hand-off” to behavioral health 
partners and outside referrals for patients with more severe alcohol problems.  A primary care 
physician noted, “When people are in the more severe category and you run out of time and you 
can hand them a list of AA meetings around the town, but it’s just so unlikely that they are going 
to access it if they haven’t already. That warm hand off process is huge.” Specialty care staff 
handled these categories on-site and referred out only patients with the most severe alcohol 
problems. 
Implementation issues.  Participants described barriers and facilitators to use of alcohol 
SBIRT for opioid agonist patients. Often, the only distinction between a facilitator and a barrier 
was its presence / absence. For example, lack of time is a barrier, while adequate time with 
patients facilitates behavioral change. Responses were grouped into four concerns: 1) 
organizational and structural, 2) provider, 3) patient and 4) community implementation. 
Implementation issues: Organizational and structural concerns.  Access to specialist 
support staff was limited in the primary care clinic. On-site social workers could not satisfy the 
demand for assistance because of competing tasks. Finance and reimbursement were issues that 
challenged both clinics, Family physicians had SBIRT billing code but did not use the codes. 
The opioid treatment program was not reimbursed for medication to reduce alcohol craving.  
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Treatment philosophies varied; the primary care clinic aimed for reduced alcohol use while the 
methadone clinic sought abstinence: “They can’t be drinking while they’re on methadone.” 
Both clinics stressed the role of electronic medical records and clinic flow. The 
methadone clinic assessed every patient for alcohol at intake but lacked a ”tick box” in their 
records to note the assessment was completed. The primary care clinic addressed clinic flows 
and integrated SBIRT into the electronic record system.  The record, however, failed to remind 
receptionists about annual screening and permitted physicians to exit the screen without 
delivering a brief intervention to positive patients: “Our whole world is now based on the 
[electronic record], everything we do has sort of a parallel virtual process that goes along with it 
and I think sometimes that becomes more our life than the reality.”  Participants from the 
specialty clinic felt that tools for decision-making and clinical guidelines would improve 
consistency of care for problem drinking: “Having a consistent way that we treat specific 
[conditions], like alcoholism with this background and this level of care would be great. So that 
we can develop patterns and know how to treat them as they go.” 
Implementation issues: Provider concerns. Training for doctors, social workers, police 
and other gatekeepers was a need in both clinics. Family doctors highlighted the importance of 
incorporating SBIRT early into resident curricula and having refresher training around brief 
interventions.  Specialty care staff echoed this need for continuing education of key gatekeepers.  
“There are some programs that are implementing some screening tools for medical professionals 
to be a little more aware of the warning signs of addiction.” 
Provider attitudes seemed to play a dominant role in addressing problem alcohol use at 
both clinics. Hypersensitivity to antagonism from patients and a lack of adequate attention to 
patient drinking led to alcohol use being overlooked.  A physician remarked, “I definitely get 
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tunnel vision around their opiate dependence and maybe like oh yeah, you’re smoking marijuana 
daily too, but we’re here about your opiates.”  When asked whether alcohol should be treated 
differently than other drugs, participants from the specialty care clinic observed that while 
content may differ the process is the same.  “When we do treatment from a bio-psycho-social 
approach, it all works no matter what drug you’re addicted to. That part of methodology is the 
same.” 
Implementation issues: Patient concerns.  Health professionals from both clinics 
perceived patient attitudes and motivations as key to addressing problem alcohol use.  One 
clinician remarked skeptically, “But, when it comes down to alcohol, it’s like the last thing that 
they have.” Other chronic conditions, comorbidity and associated risk behaviors led some 
patients to drink as a means of self-medication and hindered reduction of alcohol consumption. 
Physicians worried about opening up this complex issue and felt the system was not prepared, 
“When you know of … people who are using heroin, there’s a chance they’re using it IV, and if 
they’re using IV there’s a chance they’re accessing blood …, so if there’s people we have 
coming with Hep C that have been drinking there’s a whole other level of medical risk associated 
and it’s hard to stabilize anyone, so people are coming in ill or they have other doctors’ 
appointments or they’re just not physically able to engage in programs.”  
Finally, a key theme interwoven throughout both group discussions was patient-physician 
trust as a facilitator of treatment engagement and treatment access.  A counselor stated, 
“Engagement is key; how we treat our patient has a lot to do with what they tell us, so if the 
patients feel not judged, if they feel safe, they’re going to be more likely to engage in the 
treatment process.”  
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Implementation issues: Coordination of care.  Interagency cooperation and better 
coordination of care appeared as strong facilitators of SBIRT for opioid agonist patients, 
especially by expediting the transfer of patient records from previous treatment following 
consent to release information.  “The more information, the safer we can treat a person when 
they walk into the door, especially when medication assisted treatment is the factor.”  
Discussion 
Chart reviews suggested that most opioid dependent patients (95%) seen in a federally 
qualified health center completed a routine annual alcohol screening; elevated AUDIT scores 
were recorded for six patients (3% of those screened) and brief interventions were completed 
with five of those patients.  The methadone program, in comparison, diagnosed alcohol abuse or 
dependence at admission in 27% (n = 54) of the patient records reviewed. Patients treated in the 
methadone program appeared to have higher rates of serious alcohol use disorders than those 
who received buprenorphine in the primary care clinic.  The record reviews in both clinics 
suggested that few patients received active treatment for alcohol abuse or dependence.  Both 
clinics appear to be lax in aggressively addressing alcohol use disorders among patients treated 
for opioid dependence.   
The analysis of focus group interviews provides insights into the potential value and 
barriers to screening and treating problematic alcohol use.  Organizational, structural, provider, 
patient and community related concerns hindered or fostered alcohol screening. The most salient 
needs were continuing education for practitioners, access to specialist support staff, funding or 
reimbursement for alcohol screening and enhanced electronic medical records / clinic flows. Our 
observations support the feasibility and acceptability of implementing alcohol screening in these 
settings but suggest that most patients receive little direct care for alcohol disorders. Established 
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implementation science models can help develop strategies to address these barriers and improve 
the identification(Campbell et al. 2000; Damschroder et al. 2009). 
Previous research found similar concerns. Up to 37% patients in other opioid treatment 
programs in the U.S. screened positive for an alcohol use disorder (Hartzler, Donovan and 
Huang 2010; Ryder et al. 2009), Qualitative studies with health care providers and patients in 
other treatment programs in the U.S. noted that professional education and training and a lack of 
specialist staff were key barriers hindering management of alcohol use disorders (Field et al. 
2013; Nyamathi et al. 2009; Nyamathi et al. 2007)These findings were echoed in  our interviews 
– primary care professionals needed an extra person to perform warm hand-offs and periodic 
refresher training. The specialty care clinic, however, did not report a lack of specialist staff or 
training – they were more concerned about the funding for screening and wished to formulate 
consistent guidelines/ standards of care. Organizational differences between the primary care and 
specialty care settings differ and affect SBIRT implementation. 
Practices differed in our two settings. The primary care setting conducted open-access 
buprenorphine groups. Although not exclusively focused on problem alcohol use, the group 
appointments reduced treatment complications: “it was more about access, it wasn’t about we’re 
going to provide these wonderful group experience. We’re having [a] hard time getting our 
patients in, they no-show frequently. We open up an hour where 6-10 people can get [a] slot, 
they’re going to fill out a questionnaire, they’re going to be in the room, we’re going to answer 
their questions for 5-10 minutes and get them back individually.” In specialty care, group 
sessions were common, but not alcohol-specific. 
The primary care clinic addressed hazardous and harmful drinking using brief 
psychosocial interventions and referred dependent drinking offsite.  The specialty care clinic 
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addressed most drinking onsite, mainly with pharmacotherapy. . The specialty care clinic was 
able to accommodate such patients on-site in their facilities. The combination of alcohol 
detoxification and agonist treatment while in residential treatment can help curb drinking, 
consistent with previous research in Australia (Staiger et al. 2009). Agonist medication and 
residential treatment for alcohol should not be mutually exclusive treatment modalities. 
Strengths and Limitations  
Our research should be interpreted with caution.  The small sample comprised of clinical 
staff from only two clinics in a single U.S. city limits potential generalizability. Other limitations 
include potential for selection biases and impression management, subjectivity inherent in the 
qualitative methods utilized and other detriments of the small provider sample beyond its impact 
on generalizability.  Buprenorphine and methadone programs may serve different populations 
(Wu et al. 2011) and the alcohol assessments (AUDIT vs. DSM-IV) and care providers (i.e., 
physicians vs. counsellors) differed. Nonetheless, comparing these settings provided insights into 
areas where agonist treatment can be strengthened and streamlined with respect to the provision 
of SBIRT for alcohol use disorders. The study’s key strength is the unique combination of opioid 
agonist treatment and the SBIRT Oregon initiative at the primary care clinic that provided a rare, 
naturalistic opportunity to evaluate implementation of alcohol SBIRT for this population. 
Conclusion.  Training health professionals in alcohol screening and intervention is a 
feasible and acceptable way of improving care for opioid agonist patients.  Effective 
implementation requires systematic changes at multiple levels targeting obstacles specific to 
patient population or setting. Strategies that support implementation of SBIRT among opioid 
agonist patients, and similar vulnerable populations, include structural changes, interactive 
workshops, clinical guidelines, improved medical records and clinic workflows. These lessons 
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learned from implementation of alcohol screening within a primary care clinic can be adapted for 
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